AAPL325.13+8.28 (+2.61%) ▲|ABBV259.99+3.57 (+1.39%) ▲|ABT108.93-1.43 (-1.30%) ▼|ACN188.09-1.67 (-0.88%) ▼|ADBE286.08-6.71 (-2.29%) ▼|AMAT441.85-16.54 (-3.61%) ▼|AMD459.61-11.11 (-2.36%) ▼|AMGN438.12+8.24 (+1.92%) ▲|AMT176.02+0.32 (+0.18%) ▲|AMZN254.92-4.85 (-1.87%) ▼|AVGO369.68-0.66 (-0.18%) ▼|AXP324.19-5.98 (-1.81%) ▼|BA205.66-2.12 (-1.02%) ▼|BAC61.99+0.05 (+0.08%) ▲|BKNG195.69-3.40 (-1.71%) ▼|BLK1,128.10-27.51 (-2.38%) ▼|BMY66.92+0.11 (+0.16%) ▲|BNY160.51-0.77 (-0.48%) ▼|BRK-B502.33-1.70 (-0.34%) ▼|C132.54+0.92 (+0.70%) ▲|CAT779.16-18.31 (-2.30%) ▼|CL89.63-0.19 (-0.21%) ▼|CMCSA26.30-0.32 (-1.20%) ▼|COF211.34-3.17 (-1.48%) ▼|COP136.19+3.70 (+2.79%) ▲|COST939.96-3.93 (-0.42%) ▼|CRM258.11+0.57 (+0.22%) ▲|CSCO109.74-0.75 (-0.68%) ▼|CVS97.60+3.69 (+3.93%) ▲|CVX211.05+4.91 (+2.38%) ▲|DE676.08+21.17 (+3.23%) ▲|DHR206.93-6.63 (-3.10%) ▼|DIS106.22-1.33 (-1.24%) ▼|DUK120.39+0.48 (+0.40%) ▲|EMR147.63-4.81 (-3.16%) ▼|FDX324.88-2.52 (-0.77%) ▼|GD369.41-1.94 (-0.52%) ▼|GE331.09-4.62 (-1.38%) ▼|GEV898.53+0.00 (+0.00%) ▲|GILD149.92+3.58 (+2.45%) ▲|GM85.63-0.69 (-0.80%) ▼|GOOG332.03-3.38 (-1.01%) ▼|GOOGL335.02-4.33 (-1.28%) ▼|GS1,002.56-18.34 (-1.80%) ▼|HD319.77-8.06 (-2.46%) ▼|HON209.98-3.55 (-1.66%) ▼|IBM231.40-2.47 (-1.06%) ▼|INTC88.97-0.54 (-0.60%) ▼|INTU344.93-14.37 (-4.00%) ▼|ISRG369.25-7.61 (-2.02%) ▼|JNJ271.19+5.34 (+2.01%) ▲|JPM354.95-1.07 (-0.30%) ▼|KO88.00-0.67 (-0.76%) ▼|LIN486.76-2.82 (-0.58%) ▼|LLY1,160.00+3.27 (+0.28%) ▲|LMT544.50-13.28 (-2.38%) ▼|LOW200.05-4.65 (-2.27%) ▼|LRCX290.20-11.29 (-3.74%) ▼|MA581.10-8.21 (-1.39%) ▼|MCD261.11-0.57 (-0.22%) ▼|MDLZ61.61-0.46 (-0.74%) ▼|MDT92.04+1.39 (+1.53%) ▲|META578.54+6.20 (+1.08%) ▲|MMM170.24-1.59 (-0.93%) ▼|MO69.57+1.09 (+1.59%) ▲|MRK149.86+2.10 (+1.42%) ▲|MS211.04-2.28 (-1.07%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU933.44-25.29 (-2.64%) ▼|NEE82.93+0.59 (+0.72%) ▲|NFLX80.81-0.24 (-0.30%) ▼|NKE38.12-0.53 (-1.37%) ▼|NOW142.90-5.09 (-3.44%) ▼|NVDA217.44-3.06 (-1.39%) ▼|ORCL141.32-7.80 (-5.23%) ▼|PEP139.79-0.55 (-0.39%) ▼|PFE28.55+0.09 (+0.32%) ▲|PG146.21+1.09 (+0.75%) ▲|PLTR179.92-6.46 (-3.47%) ▼|PM187.15-0.15 (-0.08%) ▼|QCOM166.61-3.87 (-2.27%) ▼|RTX205.16-2.57 (-1.24%) ▼|SBUX106.15-0.10 (-0.09%) ▼|SCHW108.28-1.54 (-1.40%) ▼|SO88.09+0.09 (+0.10%) ▲|SPG211.87-0.45 (-0.21%) ▼|T26.00+0.11 (+0.42%) ▲|TMO600.50-16.60 (-2.69%) ▼|TMUS182.16+1.72 (+0.95%) ▲|TSLA356.09-11.86 (-3.22%) ▼|TXN253.34-7.57 (-2.90%) ▼|UBER75.24-0.41 (-0.54%) ▼|UNH396.30+6.89 (+1.77%) ▲|UNP290.62-10.05 (-3.34%) ▼|UPS102.66-1.57 (-1.51%) ▼|USB61.21-0.37 (-0.60%) ▼|V372.67-6.70 (-1.77%) ▼|VZ50.30+0.28 (+0.56%) ▲|WFC87.04+0.65 (+0.75%) ▲|WMT105.92+1.05 (+1.00%) ▲|XOM164.55+3.60 (+2.24%) ▲|AAPL325.13+8.28 (+2.61%) ▲|ABBV259.99+3.57 (+1.39%) ▲|ABT108.93-1.43 (-1.30%) ▼|ACN188.09-1.67 (-0.88%) ▼|ADBE286.08-6.71 (-2.29%) ▼|AMAT441.85-16.54 (-3.61%) ▼|AMD459.61-11.11 (-2.36%) ▼|AMGN438.12+8.24 (+1.92%) ▲|AMT176.02+0.32 (+0.18%) ▲|AMZN254.92-4.85 (-1.87%) ▼|AVGO369.68-0.66 (-0.18%) ▼|AXP324.19-5.98 (-1.81%) ▼|BA205.66-2.12 (-1.02%) ▼|BAC61.99+0.05 (+0.08%) ▲|BKNG195.69-3.40 (-1.71%) ▼|BLK1,128.10-27.51 (-2.38%) ▼|BMY66.92+0.11 (+0.16%) ▲|BNY160.51-0.77 (-0.48%) ▼|BRK-B502.33-1.70 (-0.34%) ▼|C132.54+0.92 (+0.70%) ▲|CAT779.16-18.31 (-2.30%) ▼|CL89.63-0.19 (-0.21%) ▼|CMCSA26.30-0.32 (-1.20%) ▼|COF211.34-3.17 (-1.48%) ▼|COP136.19+3.70 (+2.79%) ▲|COST939.96-3.93 (-0.42%) ▼|CRM258.11+0.57 (+0.22%) ▲|CSCO109.74-0.75 (-0.68%) ▼|CVS97.60+3.69 (+3.93%) ▲|CVX211.05+4.91 (+2.38%) ▲|DE676.08+21.17 (+3.23%) ▲|DHR206.93-6.63 (-3.10%) ▼|DIS106.22-1.33 (-1.24%) ▼|DUK120.39+0.48 (+0.40%) ▲|EMR147.63-4.81 (-3.16%) ▼|FDX324.88-2.52 (-0.77%) ▼|GD369.41-1.94 (-0.52%) ▼|GE331.09-4.62 (-1.38%) ▼|GEV898.53+0.00 (+0.00%) ▲|GILD149.92+3.58 (+2.45%) ▲|GM85.63-0.69 (-0.80%) ▼|GOOG332.03-3.38 (-1.01%) ▼|GOOGL335.02-4.33 (-1.28%) ▼|GS1,002.56-18.34 (-1.80%) ▼|HD319.77-8.06 (-2.46%) ▼|HON209.98-3.55 (-1.66%) ▼|IBM231.40-2.47 (-1.06%) ▼|INTC88.97-0.54 (-0.60%) ▼|INTU344.93-14.37 (-4.00%) ▼|ISRG369.25-7.61 (-2.02%) ▼|JNJ271.19+5.34 (+2.01%) ▲|JPM354.95-1.07 (-0.30%) ▼|KO88.00-0.67 (-0.76%) ▼|LIN486.76-2.82 (-0.58%) ▼|LLY1,160.00+3.27 (+0.28%) ▲|LMT544.50-13.28 (-2.38%) ▼|LOW200.05-4.65 (-2.27%) ▼|LRCX290.20-11.29 (-3.74%) ▼|MA581.10-8.21 (-1.39%) ▼|MCD261.11-0.57 (-0.22%) ▼|MDLZ61.61-0.46 (-0.74%) ▼|MDT92.04+1.39 (+1.53%) ▲|META578.54+6.20 (+1.08%) ▲|MMM170.24-1.59 (-0.93%) ▼|MO69.57+1.09 (+1.59%) ▲|MRK149.86+2.10 (+1.42%) ▲|MS211.04-2.28 (-1.07%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU933.44-25.29 (-2.64%) ▼|NEE82.93+0.59 (+0.72%) ▲|NFLX80.81-0.24 (-0.30%) ▼|NKE38.12-0.53 (-1.37%) ▼|NOW142.90-5.09 (-3.44%) ▼|NVDA217.44-3.06 (-1.39%) ▼|ORCL141.32-7.80 (-5.23%) ▼|PEP139.79-0.55 (-0.39%) ▼|PFE28.55+0.09 (+0.32%) ▲|PG146.21+1.09 (+0.75%) ▲|PLTR179.92-6.46 (-3.47%) ▼|PM187.15-0.15 (-0.08%) ▼|QCOM166.61-3.87 (-2.27%) ▼|RTX205.16-2.57 (-1.24%) ▼|SBUX106.15-0.10 (-0.09%) ▼|SCHW108.28-1.54 (-1.40%) ▼|SO88.09+0.09 (+0.10%) ▲|SPG211.87-0.45 (-0.21%) ▼|T26.00+0.11 (+0.42%) ▲|TMO600.50-16.60 (-2.69%) ▼|TMUS182.16+1.72 (+0.95%) ▲|TSLA356.09-11.86 (-3.22%) ▼|TXN253.34-7.57 (-2.90%) ▼|UBER75.24-0.41 (-0.54%) ▼|UNH396.30+6.89 (+1.77%) ▲|UNP290.62-10.05 (-3.34%) ▼|UPS102.66-1.57 (-1.51%) ▼|USB61.21-0.37 (-0.60%) ▼|V372.67-6.70 (-1.77%) ▼|VZ50.30+0.28 (+0.56%) ▲|WFC87.04+0.65 (+0.75%) ▲|WMT105.92+1.05 (+1.00%) ▲|XOM164.55+3.60 (+2.24%) ▲|
19.2 C
New York
Wednesday, September 2, 2026

Tag: medicine

Ductal Carcinoma In Situ Discovery from Gynecomastia Surgery by Dr Ivan Puah

Gynecomastia can indicate underlying health concerns, including cancer, and surgery provides an opportunity to examine tissues for abnormalities. Early detection saves lives. SINGAPORE, Aug. 6,...

Everhope Oncology Launches First Cancer Daycare Centre in Gurugram — Revolutionizing Cancer Care with Compassion, Precision and Convenience

Everhope Oncology takes the anxiety out of cancer treatment — with zero wait time, 2X faster service, pre-booked diagnostics, and personalised concierge-led assistance. GURUGRAM, India,...

Everest Medicines Announces Full Approval of NEFECON® in Taiwan

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

U.S., Japan, and Taiwan Experts Gather at NUWA Forum — Over 200 Reproductive Specialists Explore the Future of Integrated Fertility Technology

Is Increased Use of PGT-A Always Better? Experts Call for Evidence-Based Use of Mosaic EmbryosChoosing the Right PGT-A Platform: NUWA Fertility and Global Experts Unite...

Bracco Imaging Receives Regulatory Approval in China for SonoVue® in the Assessment of Fallopian Tube Patency

New indication of SonoVue® supports non-invasive assessment of female infertility through contrast-enhanced ultrasound in China MILAN, Aug. 5, 2025 /PRNewswire/ -- Bracco Imaging, a global...

Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management

Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders.

New revolutionary brain tech platform ‘ScreenIT’ puts smarter concussion care in reach

SYDNEY, Aug. 6, 2025 /PRNewswire/ -- A revolutionary new brain health assessment platform, ScreenIT, has officially launched, marking a major step forward in how...

Vitiligo Market to Register Incremental Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

The vitiligo market is witnessing steady growth due to rising disease awareness, improved diagnostic capabilities, and advancements in treatment options such as JAK inhibitors...

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight

The TYK2 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical...

BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its second quarter 2025 financial results after market close on Tuesday, August 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update.

Cryoport Reports Second Quarter 2025 Financial Results

Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 millionLife Sciences Services revenue rose...

UCLA to name School of Nursing for entrepreneur Joe C. Wen ’98

A transformational $30 million commitment from UCLA alumnus to support nursing education, research and practice In recognition of this transformative investment, UCLA plans to...

Cell Line and Membrane Market to Grow at 12.5% CAGR Through 2030

"Market Analysis Highlights Growth Potential, Emerging Technologies, ESG Trends, and Strategic Insights in the Cell Line and Membrane Sector" BOSTON, Aug. 5, 2025 /PRNewswire/ --...

Major Momentum in MedTech: MTEC Launches Academic Advisory Council to Supercharge Academia’s Role in Military Medical Innovation

WASHINGTON, Aug. 5, 2025 /PRNewswire/ -- Too many promising medical discoveries in university labs never make it to the battlefield, bedside, or beyond. To...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine